Today Edwards Lifesciences Corp. announced that it is acquiring Corvia Medival for $35 million. The company’s InterAtrial Shunt Device is designed to reduce the symptoms or slow the progression of heart failure by providing continuous and dynamic decompression of the left atrium. The technology is the ”first transcatheter device to treat heart failure with preserved or mid-range fraction,” according to an Edwards news release. It has the CE Mark and is currently in an FDA pivotal clinical trial.
Edwards also announced that is acquiring assets of Mitralign, Inc. that includes intellectual property, and related clinical and regulatory experience. The company’s Trialign System is an investigational transcatheter annuloplastry system in the United States that is intended to treat functional and mitral and tricuspid regurgitation.
It’s been a busy 30 days for the company. Last month it acquired CAS Medical Systems for $100 million.